Due to safety and efficacy issues, 35 Billion USD was spent in unsuccessful clinical trials and procedures last year. In order to avoid this loss, pharmaceutical companies need to adopt new technologies in the Drug Development cycle. The usage of stem cells in the screening process has high potential in achieving cost and time reductions across the drug development cycle of a drug. The whitepaper talks about the adoption of this technology with an emphasis on the emergence of a new class of service providers in the area of drug discovery.
Share this Whitepaper